Beta Bio Reports Q3 2026 Net Sales of $35.5 Million and Raises Revenue Guidance

Beta Bio (BBNX) reported third-quarter 2026 net sales of $35.5 million, driven by the increasing adoption of its automated insulin delivery platform. Following these results, management raised the low end of its full-year 2026 revenue guidance to $124 million, up from $121 million, while maintaining a high-end target of $126 million. The company is preparing for the Q1 2027 commercial launch of 'Mint,' an FDA-cleared tubeless patch pump designed to expand its market share. Additionally, Beta Bio is working to resubmit its 510(k) application for its 3D Intelligence dosing algorithm in mid-Q4 2026 following regulatory feedback regarding simulator validation tests.

4 articles from 2 sources · updated

Coverage